Alector (NASDAQ:ALEC) Insider Grace Wong-Sarad Sells 5,165 Shares of Stock

Posted by George Bondi on Sep 4th, 2026

Alector, Inc. (NASDAQ:ALEC – Get Free Report) insider Grace Wong-Sarad sold 5,165 shares of Alector stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $2.67, for a total value of $13,790.55. Following the sale, the insider directly owned 109,640 shares of the company’s stock, valued at $292,738.80. This trade represents a 4.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Grace Wong-Sarad also recently made the following trade(s):

On Friday, September 4th, Grace Wong-Sarad sold 3,625 shares of Alector stock. The stock was sold at an average price of $2.51, for a total value of $9,098.75.
On Wednesday, September 2nd, Grace Wong-Sarad sold 656 shares of Alector stock. The shares were sold at an average price of $2.75, for a total value of $1,804.00.

Alector Stock Down 2.0%

Shares of NASDAQ ALEC traded down $0.05 during midday trading on Friday, hitting $2.46. 496,599 shares of the company’s stock were exchanged, compared to its average volume of 882,288. The company has a debt-to-equity ratio of 0.80, a current ratio of 5.26 and a quick ratio of 5.26. Alector, Inc. has a twelve month low of $1.09 and a twelve month high of $3.40. The company has a market cap of $274.68 million, a PE ratio of -2.24 and a beta of 0.65. The firm’s fifty day simple moving average is $1.89 and its 200-day simple moving average is $2.05.

Alector (NASDAQ:ALEC – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.02. The firm had revenue of $3.32 million during the quarter, compared to the consensus estimate of $1.71 million. Alector had a negative return on equity of 531.03% and a negative net margin of 850.13%. Research analysts predict that Alector, Inc. will post -0.87 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. Wall Street Zen upgraded shares of Alector from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings raised Alector from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Alector currently has an average rating of “Hold” and a consensus target price of $3.62.

Check Out Our Latest Stock Analysis on ALEC

Hedge Funds Weigh In On Alector

A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. purchased a new stake in Alector in the 2nd quarter valued at $15,774,000. Vanguard Group Inc. grew its position in Alector by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 6,034,659 shares of the company’s stock worth $17,863,000 after purchasing an additional 46,955 shares during the last quarter. Nantahala Capital Management LLC purchased a new position in Alector during the 2nd quarter worth $8,679,399. Foresite Capital Management IV LLC purchased a new position in Alector during the 4th quarter worth $6,064,000. Finally, Merck & Co. Inc. acquired a new position in Alector in the second quarter valued at $7,126,896. 85.83% of the stock is currently owned by hedge funds and other institutional investors.

About Alector

(Get Free Report)

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.